Inactive Instrument

Highlights Vifor Pharma AG SIX SWISS EXCHANGE - BLUE CHIPS SEGMENT

Equities

VIFN

CH0364749348

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

European Commission Solicits Feedback on Vifor Pharma's Anticompetition Commitments	Apr. 19	MT
CSL Vifor Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis	23-05-02	CI
Court Cancels Public Shares of Vifor Pharma after Merger with CSL	22-12-14	MT
Rhythm Biosciences Expands Executive Management Team, Registers Diagnostic Blood Test With New Zealand	22-11-02	MT
Australia's CSL raises annual profit forecast on Swiss acquisition	22-10-16	RE
Vifor Pharma Gets Approval To Delist From Swiss Bourse	22-10-12	MT
Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	22-09-27	MT
Fitch Pulls Vifor Pharma's Rating After CSL Takeover	22-08-25	MT
Vifor, Travere's Application for Rare Kidney Disease Drug Under Review in EU	22-08-22	MT
Vifor-Fresenius Medical Care JV Wins US Infringement Case Against Teva	22-08-22	MT
UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease	22-08-18	MT
Australia biotech giant CSL reports profit dip, flags cost spiral	22-08-16	RE
Australia's CSL Closes Vifor Pharma Purchase	22-08-10	MT
CSL Completes Vifor Pharma Acquisition	22-08-10	MT
CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders.	22-08-08	CI
CSL Receives All Regulatory Approvals for Vifor Pharma Acquisition	22-08-01	MT
Australia's CSL Further Delays Settlement Of Vifor Pharma Takeover	22-07-13	MT
European Commission to Probe Vifor Pharma Over Alleged Anti-Competitive Behavior	22-06-20	MT
EU regulators investigate Vifor Pharma over anti-competitive behaviour	22-06-20	RE
Fitch Puts Vifor Pharma on Rating Watch Positive on CSL Takeover	22-06-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vifor Pharma AG SIX SWISS EXCHANGE - BLUE CHIPS SEGMENT

Equities

VIFN

CH0364749348

Highlights

Filters